company coverage
Neuren Pharmaceuticals Limited ASX research
Coverage of Neuren Pharmaceuticals Limited collects dated research on business quality, return drivers, balance-sheet resilience, valuation scenarios, and what would change the thesis for ASX:NEU.
1 edition linked in this hub.
Coverage
- 29 June 2026Neuren's European Daybue jump puts one-drug royalties ahead of the pipelineNeuren (ASX:NEU) jumped after Daybue won an EU approval positive opinion; the question is how much royalty duration the tape just capitalised.